Skip to content
Wednesday, November 18, 2026
Explore the latest casino bonuses and promotions at Fresh B…

Users Discontinuing Weight-Loss Injections Put On Weight at a Quadrupled Rate Than People Using Diet and Exercise

Illustration of medical injection and weighing machine
Obesity treatment involves long-term strategies.

Fresh analysis indicates that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop conventional diet and exercise plans.

Published data in a major medical journal demonstrates that while obese individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.

"Individuals buying such medications must be cognizant of the danger of fast rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.

Such speed of regain implies a return to pre-treatment mass within about a year and a half.

Weighing Approaches

The study, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with conventional dieting.

Researchers point out that individuals who shed pounds through dieting usually have a more gradual weight regain—perhaps 0.1 kg a month—after stopping.

Understanding the Fast Regain

Doctors suggest the mechanism of the jabs explains the amplified weight return.

The injections imitate a natural hormone called GLP-1, which moderates hunger.

"Sustained high doses of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this medication results in hunger is unsuppressed, making overeating far more likely."

A Lifelong Issue?

The NHS advise the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.

Many experts argue that, due to the high risk of weight regain, the therapy should be considered ongoing.

This view is echoed by pharmaceutical companies, who say that the results "emphasize the long-term character of obesity," similar to managing conditions like hypertension.

Patient Testimonies

Individuals who have come off the medication describe a intense return of appetite.

"It was like a trigger activating and I was suddenly extremely hungry," said an individual.

This challenge is worsened if users have not developed sustainable lifestyle or habit changes during therapy.

Growing Use

Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.

  • Use is greater among females compared to men.
  • The 40s and 50s demographic shows the highest level of interest.
  • A large proportion access the medications through private healthcare rather than public health services.

In conclusion, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and maintained weight loss hinges on combined lifestyle support.

RP
Written by

Ronald Phillips

Elena Rivas is a casino bonus expert with over a decade of experience in the iGaming industry.

Fresh Bonus Link

Type to search articles.